0.16
+0(+0.00%)
Currency In USD
Address
2 Bloor Street West
Toronto, ON M4W 3E2
Canada
Phone
416 648 5555
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
November 13, 2017
| Name | Title | Pay | Year Born |
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, President & Chief Executive Officer | 328,397 | 1957 |
| Ms. Elizabeth Williams C.A., CPA, CA, CPA | Chief Financial Officer & Corporation Sec. | 231,045 | 1978 |
| Mr. Brent Meadows M.B.A. | Chief Business Officer | 0 | N/A |
| Dr. Humphrey A. R. Gardner FCAP, M.D. | Chief Medical Officer | 0 | N/A |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor | 0 | N/A |
| Mr. Jeff Caravella M.B.A. | Chief Financial Officer | 0 | N/A |
| Dr. Martin Bexon M.D., MBBS | Acting Chief Medical Officer & Head of Clinical Devel. | 0 | N/A |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.